#USA #Miami Beach #Immorta Bio #SenoVax #mRNA Therapy

Immorta Bio Unveils Patented SenoVax™ Immunotherapy

Immorta Bio Inc., a revolutionary company striving for scientific breakthroughs in longevity, has recently announced an international patent application for its novel product, SenoVax™. This innovative therapy specifically addresses the dual challenges of aging and cancer, positioning itself as a leading candidate in the fight against diseases that afflict older populations.

What is SenoVax™?

SenoVax™ is described in the patent under the title "Senescence Vaccine." The technology behind it is aimed at stimulating the immune system to selectively target and eliminate senescent cells—those dysfunctional cells that accumulate as we age. These cells are known to contribute to various age-related declines, including inflammation, organ failures, and provide a conducive environment for tumor growth.

The significance of effectively removing these senescent cells cannot be overstated, as it fosters a broad anti-aging effect while simultaneously mitigating the progression of cancer, addressing two critical underlying causes of agerelated health issues.

Clinical Insights from Immorta Bio

Dr. Thomas Ichim, the President and Chief Scientific Officer at Immorta Bio, emphasized the groundbreaking nature of SenoVax™. He pointed out that by eradicating senescent cells, this therapy not only promotes the elimination of aging-associated biology but also disrupts tumor-supportive microenvironments necessary for cancer survival. This dual-action capability makes SenoVax™ a pioneering approach in immunotherapy.

The data surrounding SenoVax™'s efficacy have shown promising results. Specifically, it demonstrated significant reductions in established cancer types, including lung, breast, brain, skin, and pancreatic cancers in preclinical models. This potent anti-cancer activity is underscored by the ongoing submission of Investigational New Drug (IND) application #30745 to the FDA, focused specifically on advanced lung cancer treatment.

A Comprehensive Strategy for Longevity

In addition to SenoVax™, Immorta Bio is committed to a broader strategy aimed at combating aging by integrating another of their innovative platforms, StemCellRevivify™. This platform seeks to introduce young, organ-specific progenitor and mesenchymal stem cells to restore the body’s regenerative capabilities. Together, they aim to effectively target two of the fundamental drivers of aging: the impaired clearance of damaged cells and the loss of tissue regeneration.

As Dr. Boris Reznik, the Chairman and CEO of Immorta Bio, states, “Cancer is the most prevalent disease of aging, and SenoVax™ allows us to attack both aging biology and tumor biology at the same time.” The ultimate goal is to affirm safety and efficacy within advanced cancer patients, expanding further into the treatment of age-related conditions and ultimately challenging the aging process itself.

The Future of Anti-Aging and Cancer Therapies

The publication of this international patent underscores Immorta Bio's unique position in the field of longevity and oncological therapies. They stand out as the only company developing a dual-platform solution that deals not only with the general aspects of aging but also addresses its most lethal manifestations. Current preclinical evidence indicates noteworthy benefits across multiple cancer models, aging and frailty models, as well as organ-failure models, leading to reported lifespan extensions exceeding 100% alongside improvements in healthspan.

In summary, Immorta Bio is at the forefront of a transformative approach in healthcare, focusing on reversing the impacts of age and treating the diseases associated with it. With products like SenoVax™ and StemCellRevivify™, they are setting the stage for a new era in regenerative medicine and cancer therapy.